and actually Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical) Overview Side Effects Professional Interactions Pregnancy More User Reviews Pronunciation (bas i TRAY sin, nee oh MYE sin, pol i MIKS in bee, & hye droe KOR ti sone) Index Terms Hydrocortisone, Bacitracin, Neomycin, and Polymyxin B Neomycin, Bacitracin, Polymyxin B, and Hydrocortisone Polymyxin B, Bacitracin, Neomycin, and Hydrocortisone Slideshow Flagyl Side Effects and What You Can Do About Them Dosage Forms Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Ointment, External: Cortisporin: Bacitracin 400 units, neomycin 3.5 mg, polymyxin B 5000 units, and hydrocortisone 10 mg per g (15 g) Brand Names: U.S. Cortisporin Pharmacologic Category Antibiotic, Topical Corticosteroid, Topical Pharmacology See individual agents. Use: Labeled Indications Superficial dermal infection: Treatment of corticosteroid-responsive dermatoses with secondary infection Contraindications Hypersensitivity to bacitracin, neomycin, polymyxin B, hydrocortisone, or any component of the formulation. Dosing: Adult Superficial dermal infection: Topical: Apply sparingly to affected area 2 to 4 times daily for up to 7 days Dosing: Geriatric Refer to adult dosing. Dosing: Renal Impairment There are no dosage adjustments provided in the manufacturer's labeling. Dosing: Hepatic Impairment There are no dosage adjustments provided in the manufacturer's labeling. Administration Topical: For external use only. Apply sparingly to the affected area. Limit therapy to 7 days of treatment. Storage Store at 15 C to 25 C (59 F to 77 F). Drug Interactions Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Monitor therapy Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification Adverse Reactions See individual agents. Warnings/Precautions Concerns related to adverse effects: Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002). Neomycin sensitization: Neomycin may cause cutaneous sensitization. Symptoms of neomycin sensitization include itching, reddening, edema, and failure to heal. Discontinuation of product and avoidance of similar products should be considered. Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas. Neomycin can induce permanent sensorineural hearing loss due to cochlear damage; risk is greater with prolonged use. Special populations: Pediatric: Topical corticosteroids: Infants and small children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects due to larger skin surface area to body mass ratio, particularly if applying to >20% of BSA. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients. Dosage form specific issues: Topical ointment: Limit therapy to 7 days of treatment. Pregnancy Risk Factor C Pregnancy Considerations Adverse events have been observed with topical corticosteroids in animal reproduction studies. Refer to individual agents. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience dry skin or burning. Have patient report immediately to prescriber severe skin irritation, severe skin pain, redness, edema, or signs of skin changes (acne, stretch marks, slow healing, or hair growth) (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about bacitracin/hydrocortisone/neomycin/polymyxin b topical Side Effects During Pregnancy Drug Interactions 0 Reviews Add your own review/rating Drug class: topical steroids with anti-infectives Consumer resources Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical) Professional resources Other brands: Cortisporin Ointment Related treatment guides Bacterial Skin Infection Dermatitis Paronychia Antibiotics 101 Everything you need to know about antibiotics: List of Common Antibiotics & Types Antibiotics & Drinking Alcohol - Is it Safe? Antibiotics For UTI - What Are My Options? Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Bacitracin / hydrocortisone / neomycin / polymyxin b topical Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Topical steroids with anti-infectives Related Drugs topical steroids with anti-infectives Lotrisone , Mycolog II , betamethasone / clotrimazole topical , nystatin / triamcinolone topical , Cortisporin Cream Bacterial Skin Infection Bactrim , sulfamethoxazole / trimethoprim , Bactrim DS , bacitracin topical , tetracycline topical , Septra , Neosporin , SMZ-TMP DS , More... Paronychia nystatin topical , clotrimazole topical , mupirocin topical , gentamicin topical , econazole topical , More... Dermatitis fluticasone topical , triamcinolone , hydrocortisone topical , prednisolone , clobetasol topical , betamethasone topical , doxepin topical , More... it also includes
facts Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone (Topical) it's vital
EmoticonEmoticon